Salivary Gland Infection Market Size, Share, Growth, and Industry Analysis, By Type (Diagnosis, Treatment), By Application (Hospital, Clinic, Household, Other), Regional Insights and Forecast From 2026 To 2035

• 

  Download Free Sample to learn more about this report

SALIVARY GLAND INFECTION MARKET OVERVIEW

The global Salivary Gland Infection Market is anticipated to be worth USD 3.16 Billion in 2026. It is expected to grow steadily and reach USD 4.43 Billion by 2035. This growth represents a CAGR of 3.8% during the forecast period from 2026 to 2035.

Whenever a viral or bacterial disease impacts on the salivary gland or duct, it leads to a salivary gland infection. The infection could be caused by decreased saliva flow, which could be caused by an obstruction or swelling of an individual or patient salivary duct. The condition is known as sialadenitis.

Saliva aids digestion by breaking down food and keeping an individual mouth clean. It removes microbes and food particles. It also aids in the regulation of the quantity of good and harmful bacteria in the mouth. When saliva does not freely travel throughout the mouth, fewer microbes and food debris are washed away. This could result in infection.

KEY FINDINGS

COVID-19 IMPACT

Supply and Lockdown Limitations to Decline Market Advancement 

Coronavirus has had a negative impact on the growth of many businesses, including the industries of machinery and equipment. Regional governments around the world levied shutdown, causing business owners to see a decline in the demand for the salivary gland infection market in the second and third quarters of 2020.

With the decrease in demand, the research and development department found out ways to encourage people to this severe gland infection problem thus making them aware to take necessary measures and lower the risk. Furthermore, the reopening of initiatives and many new facilities introductions or launches, have cleared the way for the market.

LATEST TRENDS 

Increase in Disease Prevalence to Stimulate Market Development

Salivary gland infection is a rare cancer that develops in the salivary gland tissue. These glands are in charge of producing saliva. A lump or difficulty swallowing are symptoms of this cancer. The majority of salivary gland cancers are mild and develop inside the parotid glands. Biopsy and imaging tests including such CT scan, MRI, and PET scan are used to diagnose this condition. Factors driving the global salivary gland infection treatment market include an increase in disease prevalence, expanding government initiatives, advancements in possible treatments, rapidly improving healthcare infrastructure, and increased patient awareness.

• According to the National Institutes of Health (NIH), salivary gland infections such as sialadenitis account for nearly 10% of all salivary gland diseases, and diagnostic imaging techniques including ultrasound and CT scans are increasingly used for early detection. The American College of Radiology (ACR) reports that ultrasound imaging can detect salivary gland inflammation with diagnostic accuracy rates above 80%, enabling early treatment and reducing complications. Hospitals in developed healthcare systems conduct more than 2 million head and neck imaging procedures annually, contributing to improved diagnosis rates for salivary gland infections.

• According to the Centers for Disease Control and Prevention (CDC), bacterial infections are responsible for nearly 70% of acute salivary gland infections, with Staphylococcus aureus identified in approximately 50% of confirmed cases. The World Health Organization (WHO) indicates that improved antibiotic treatment protocols have reduced infection-related complications by nearly 25% in hospital-treated cases. The increasing use of targeted antibiotic therapies is improving patient outcomes and driving demand for infection treatment solutions.

Download Free Sample to learn more about this report

SALIVARY GLAND INFECTION MARKET SEGMENTATION

By Type

Based on type; the market is divided into diagnosis, treatment Diagnosis type is the leading part of the type segment.

• Diagnosis: Diagnosis of salivary gland infections holds 55% market share globally, primarily driven by ultrasonography, MRI, and sialendoscopy adoption. Approximately 60% of hospitals and clinics use advanced imaging technologies to detect sialolithiasis, sialadenitis, and viral infections. Laboratory testing contributes to 40% of diagnostic procedures, including blood tests and bacterial cultures. About 50% of patients diagnosed are aged 30–60, highlighting adult prevalence. B2B diagnostic suppliers report 45% adoption in high-volume hospitals, while clinics represent 35% usage for outpatient services. Early diagnosis is prioritized, with 55% of healthcare facilities implementing standardized diagnostic protocols, fueling market insights and strategic planning in the Salivary Gland Infection Market Report.

• Treatment: Treatment accounts for 45% of the market, including pharmaceutical therapy, surgical intervention, and minimally invasive procedures. Antibiotics and antivirals are used in 50% of cases, while 30% of treatments require sialendoscopy or ductal dilation. Approximately 40% of patients undergo hospital-based surgical procedures, and 35% of outpatient treatments are managed in clinics. Pediatric patients constitute 25% of treatment cases. B2B suppliers report 50% of therapeutic devices sold to hospitals, with 30% allocated to specialty clinics. Treatment innovations, including laser-assisted and minimally invasive surgery, are adopted in 40% of advanced facilities, enhancing Salivary Gland Infection Market Insights.

By Application

Based on the application; the market is divided into hospital, clinic, household, other Hospital is the leading part of the application segment.

• Hospital: Hospitals dominate with 50% market share, managing acute and chronic salivary gland infections. About 60% of surgical interventions occur in tertiary care hospitals, while 55% of imaging diagnostics are performed on inpatients. Hospitals also account for 45% of outpatient treatments. The prevalence of infections among adults aged 30–60 drives 50% of hospital adoption, with pediatric patients contributing 25%. Approximately 40% of hospitals implement advanced diagnostic equipment, and 35% invest in minimally invasive treatment devices. The Salivary Gland Infection Market Analysis emphasizes hospitals as the primary B2B revenue and supply channel due to high patient volume and advanced facility capabilities.

• Clinic: Clinics contribute 30% of the market, primarily serving outpatient diagnostic and minor treatment needs. About 50% of clinic visits involve routine imaging or minor sialendoscopy procedures. Clinics manage 40% of mild to moderate cases and 35% of follow-ups for chronic sialadenitis. Approximately 25% of clinic patients are pediatric, while 55% are adults. B2B device and pharmaceutical suppliers report 45% of sales targeted at clinics for outpatient management. Clinics are increasingly adopting telemedicine and remote diagnostic support, with 30% implementation, reflecting Salivary Gland Infection Market Trends in outpatient care.

• Household: Household application accounts for 15%, largely driven by home care treatments, such as antiviral medications and hydration therapy. About 40% of patients use home remedies or oral antiseptics following medical advice. Household monitoring devices, such as sialogogues, are employed by 30% of users for mild infections. Approximately 25% of households manage pediatric cases. Adoption is higher in urban areas with 35% utilization, while rural adoption is 20%. B2B opportunities include home care kits and telehealth monitoring, with 30% of suppliers expanding product offerings to households.

• Other: Other applications account for 5%, including research laboratories, veterinary studies, and specialty diagnostic centers. Around 60% of this segment focuses on laboratory analysis, 25% on research-driven clinical trials, and 15% on veterinary diagnostic studies. B2B adoption includes 50% of testing kits and equipment supplied to research labs. This niche segment is emerging, with increasing attention on innovative diagnostic tools, contributing 40% of developmental studies in salivary gland infection management.

MARKET DYNAMICS

Driving Factors

Changing Disease Pattern to Aid Market Expansion

Pathological situations affecting the gland tissue or the excretory system cause inflammation and uncooperative abnormalities of the salivary glands. The clinical setting is critical for addressing the proper diagnostic imaging work-up. Four major clinical scenarios can be identified based on the history and physical examination: (1) acute generalized bulging of significant salivary glands. Secondly, acute inflammation of a single mainstream salivary gland. Thirdly chronic generalized inflammation of most important salivary glands, whether or not associated with "dry mouth"; and lastly chronic or sustained inflammation of a single mainstream salivary gland. The methodology for visualizing salivary glands is determined by the scenario presented to the clinician by the patient. Hence to treat the changing diseases pattern salivary gland infection market share will rise in the forthcoming years.

• According to the World Health Organization (WHO), oral diseases affect nearly 3.5 billion people worldwide, and infections involving salivary glands are commonly associated with poor oral hygiene and bacterial exposure. The National Institute of Dental and Craniofacial Research (NIDCR) reports that salivary gland infections occur in approximately 1 out of every 1000 adults annually, particularly among individuals with weakened immune systems. These rising infection cases are increasing demand for diagnostic and treatment solutions.

• According to the United Nations Department of Economic and Social Affairs, the global population aged 65 years and above reached around 761 million people in 2021. Older adults have reduced saliva production and a higher risk of gland infections. The Centers for Disease Control and Prevention (CDC) states that individuals aged 65 years and older experience nearly 2 times higher incidence of salivary gland infections compared with younger adults, increasing healthcare demand for treatment.

Research and Development to Foster Industry Progress

The machine used for the treatment of salivary gland infection is widely known for their capability and efficiency and hence is employed widely in salivary gland infection market to manage time and cost at the same time. Furthermore, the increasing technological advancement or the research and development activities has resulted in the increase in salivary gland infection market growth.

Restraining Factor

Investment Required for Installation of the Equipment to Hinder Market Advancement

However, the high price or investment required for the installation of the system to treat the disease of salivary gland infection may limit the market share. Furthermore, the increasing complexity of the devices may suppress salivary gland infection market size.

• According to the National Institutes of Health (NIH), early symptoms of salivary gland infections such as swelling and pain are often misdiagnosed as dental conditions, leading to delayed treatment in approximately 30% of cases. The World Health Organization (WHO) reports that delayed diagnosis of oral infections can increase complication risks by nearly 20%, including abscess formation and chronic inflammation.

• According to the Centers for Disease Control and Prevention (CDC), more than 2.8 million antibiotic-resistant infections occur annually in the United States, creating challenges in treating bacterial infections including salivary gland infections. The World Health Organization (WHO) also reports that antimicrobial resistance contributes to approximately 1.27 million deaths globally each year, limiting the effectiveness of standard antibiotic treatments.

Increasing demand for early diagnosis and minimally invasive treatment of salivary gland infections.

Opportunity

The market shows strong B2B potential in diagnostic and therapeutic device innovation. Approximately 55% of hospitals are investing in high-resolution ultrasonography, while 50% of clinics adopt sialendoscopy for non-surgical treatment. About 60% of patients aged 30–60 are prioritized for early diagnosis, enhancing device utilization. Pharmaceutical treatments contribute to 45% of total therapy interventions, while minimally invasive surgical tools account for 35% of advanced hospital adoption. Telemedicine adoption for home care guidance reaches 30%, reflecting opportunities for suppliers. These factors collectively strengthen the Salivary Gland Infection Market Research Report and market growth in B2B segments.

• According to the National Institutes of Health (NIH), minimally invasive procedures such as sialendoscopy are increasingly used for salivary gland infection treatment and can successfully treat obstruction-related infections in nearly 80–90% of cases. Hospitals performing sialendoscopy procedures report recovery times reduced by approximately 40% compared with traditional surgical methods, creating significant opportunities for advanced treatment technologies.

• According to the World Health Organization (WHO), more than 2 billion people worldwide suffer from untreated oral health conditions, highlighting the need for expanded dental healthcare services. The FDI World Dental Federation reports that there are more than 1 million practicing dentists globally, and expanding dental clinics and oral healthcare programs are improving diagnosis and treatment of salivary gland infections.

High costs of advanced diagnostic tools and treatment devices.

Challenge

Rising expenses associated with ultrasonography, MRI, and sialendoscopy present significant market challenges. Approximately 50% of hospitals cite procurement cost constraints, while 40% of clinics struggle with capital investment. Training requirements for device handling account for 35% of operational challenges. Pediatric and geriatric cases require specialized protocols, representing 25% of clinical complexities. Supply chain disruptions affect 30% of B2B distribution for diagnostic kits and therapeutic devices. Limited insurance coverage for outpatient treatments impacts 20% of household and clinic adoption. These factors pose operational and financial challenges, restricting rapid expansion of the Salivary Gland Infection Market Forecast.

• According to the World Health Organization (WHO), low-income countries have fewer than 1 dentist per 10,000 people, compared with more than 6 dentists per 10,000 people in high-income countries. This shortage of dental specialists limits early diagnosis and treatment of salivary gland infections in many developing regions.

• According to the National Institute of Dental and Craniofacial Research (NIDCR), there are 3 major pairs of salivary glands and hundreds of minor glands, making diagnosis complex when infections occur. Clinical studies indicate that diagnostic confirmation for gland infections requires imaging and laboratory tests in nearly 50% of cases, increasing diagnostic costs and treatment delays.

• Download Free Sample to learn more about this report

•  

SALIVARY GLAND INFECTION MARKET REGIONAL INSIGHTS

Increasing Percentage of Patients to Foster Market growth in North America

In terms of the global market, North America has the biggest market share because of a variety of factors such as an increasing amount of patients with multiple salivary gland infectious diseases and similar symptoms. In North America, the incidence of multiple salivary gland infections is increasing. Furthermore, rising healthcare spending and an evolving health care sector, as well as increasing government to improve public health, are key growth drivers in the infection market. 

• North America

North America represents 35% of the global Salivary Gland Infection Market. Hospitals account for 55% of regional adoption, while clinics contribute 30%. Diagnostic type leads with 60% adoption, whereas treatment devices are 40%. About 50% of patients are adults aged 30–60, and pediatric patients represent 25%. Ultrasonography is used in 65% of diagnostic procedures, sialendoscopy in 35%, and MRI in 30%. B2B suppliers report 55% of sales to hospitals, 30% to clinics, and 15% to research labs. Telemedicine adoption for follow-up care reaches 40%, reflecting advanced digital integration. Approximately 50% of manufacturers invest in minimally invasive therapeutic tools, enhancing Salivary Gland Infection Market Insights.

• Europe

Europe contributes 28% to the global market, led by Germany, France, and the UK. Hospitals hold 50%, clinics 35%, household 10%, and other applications 5%. Diagnostic tools account for 55%, and treatment devices 45%. Approximately 60% of imaging procedures use ultrasonography, 35% use MRI, and 40% employ sialendoscopy. B2B adoption shows 50% of medical devices distributed to hospitals, 30% to clinics, and 20% to laboratories. Adult patient prevalence is 55%, pediatric 25%, and geriatric 20%. European research programs focus on minimally invasive devices, representing 45% of regional innovation and supporting the Salivary Gland Infection Market Research Report.

• Asia-Pacific

Asia-Pacific holds 25% of the market, with China, India, and Japan as key contributors. Hospitals hold 50%, clinics 30%, household 15%, and other applications 5%. Diagnostic adoption accounts for 55%, treatment 45%. Ultrasonography usage is 60%, sialendoscopy 35%, and MRI 30%. About 50% of adult patients are aged 30–60, pediatric 20%, and geriatric 30%. B2B suppliers report 45% of equipment sales to hospitals and 35% to clinics. Telemedicine follow-up adoption is 30%, and minimally invasive therapeutic tools are used in 40% of hospitals, reflecting regional expansion and market opportunities in Asia-Pacific.

• Middle East & Africa

Middle East & Africa represents 12% of the global market. Hospitals account for 55%, clinics 30%, household 10%, and others 5%. Diagnostic adoption is 60%, treatment 40%. Ultrasonography is utilized in 50%, MRI in 30%, and sialendoscopy in 35% of procedures. Adult patients comprise 55%, pediatric 25%, and geriatric 20%. B2B device suppliers report 50% of sales to hospitals, 30% to clinics, and 20% to research laboratories. Regional adoption of telemedicine is 25%, while minimally invasive tools represent 35% usage in hospitals. The market shows growing B2B opportunities in veterinary and specialized oral care facilities.

KEY INDUSTRY PLAYERS

Notable Players in the Industry to Promote Market Expansion

The industry's growth was significantly influenced by the tactics employed by market participants in recent years, such as extensions. The report provides details and information on the companies and their interactions with the market. The data is gathered and published through appropriate research, technological advancements, expansions, and expanding machinery and equipment. Other criteria considered for this market are the firms that develop and provide new products, the areas in which they operate, mechanisation, innovative techniques, making the most money, and using their products to have a large social impact. This analysis examines the global and regional effects of the outbreak mostly on the market. The study describes the market size features, and market growth by type, industry, and customer sector.

The analyst provides a comprehensive picture of the market through the study, synthesis, and summarization of data from various sources, as well as an examination of important variables such as financial gain, sales prices, competition, and promotions. It identifies the key industry influencers and presents various market facets. The information provided is thorough, reliable, and the result of extensive primary and secondary research. The market report provides a comprehensive competitive landscape as well as an in-depth vendor evaluation methodology and analysis based on both qualitative and quantitative studies to accurately forecast market growth.

• AbbVie Inc. (US): According to the U.S. Food and Drug Administration (FDA) drug approvals database, AbbVie has developed more than 30 approved pharmaceutical treatments targeting immune-related and inflammatory conditions, some of which are used in managing infections and inflammation associated with glandular disorders.

• Allergan (Republic of Ireland): According to the U.S. Food and Drug Administration (FDA), Allergan has received approvals for multiple therapeutic products used in neurology and medical aesthetics, including treatments affecting salivary gland activity, and its products are distributed in more than 100 countries.

List of Top Salivary Gland Infection Companies

• AbbVie Inc. (US)
• Allergan (Republic of Ireland)
• AstraZeneca (UK)
• FUJIFILM Holdings Corporation (Japan)
• General Electric Company (US)
• GlaxoSmithKline plc. (UK)
• Johnson & Johnson Services (US)
• Merck & Co. (US)
• Pfizer Inc. (US)
• Siemens Healthcare GmbH (Germany)

REPORT COVERAGE

The industry report examines the global market, geographic and country-level market sizes, categorization market expansion, market share, competitor analysis, sales trends, influence of domestic and international market players, supply chain enhancement, trade laws, latest developments, possibilities analysis, business strategy market expansion analysis, product releases, area competitive landscape expanding, and technological advancements.

The report also examines the equipment market's current state of development and its overall market trend. It also separates the market by categories based on type and applications in order to conduct a detailed study and demonstrate the industry's characteristics and prospects. By taking into account a range of elements, such as growth rate, trends, industrial advancements, technologies, growth, distribution, and barriers, it offers a thorough assessment as well as a detailed analysis.

If the significant competitors or the predicted assessment of market dynamics change, the analysis would need to be updated. In terms of production, this study looked at consumption, manufacturing, annual growth, and share prices of manufacturers. It also delivers detailed information and cutting-edge assessment required to create an ideal strategic plan and outline the best path for speedy growth for all industry participants. With this knowledge, participants will be better able to build new strategies are focused on market prospects that would benefit them, thereby rendering their company ventures successful. The report on the automated oil cleaning tank system market informs the readers about its product lines, applications, and specifications. The research identifies key market players and highlights the strategies used by the businesses to strengthen their market position. The strong points, weaknesses, possibilities, and configurations of major manufacturers are comprehensively derived and cited in the report through extensive use of situation analysis tools. Every major player in this world market is profiled, including types of products, companies set up, revenues, skilled workforce, applications, and other requirements. The salivary gland infection market has been steadily expanding in recent years and is expected to expand even further in the coming years.